Phenotypic spectrum and diagnostic evolution in GLUT1 deficiency syndrome: a single-centre adult cohort experience
This single-centre retrospective study of 31 adult patients with GLUT1 deficiency syndrome highlights the condition's significant phenotypic heterogeneity and evolving diagnostic landscape, demonstrating how the shift toward exome and whole-genome sequencing alongside cascade testing has facilitated the identification of milder, atypical, and later-onset cases that were previously missed.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The brain is an engine that never stops running, consuming a vast amount of energy just to keep the lights on. Unlike muscles, which can switch to burning fat or stored sugar when food is scarce, the brain relies almost exclusively on a single fuel source: glucose. To get this fuel from the bloodstream into the brain, it must cross a protective barrier known as the blood-brain barrier. This crossing is not automatic; it requires a specific gateway protein, a transporter that acts like a dedicated door, to shuttle glucose molecules inside. When this door is broken or missing, the brain's energy supply is cut off, leading to a cascade of neurological problems. This condition, known as GLUT1 deficiency syndrome, has long been recognized as a severe disorder affecting infants, characterized by uncontrollable seizures and developmental delays. However, as medical understanding deepens, doctors are realizing that the damage caused by a faulty glucose door can look very different depending on the patient, sometimes appearing much later in life and with symptoms that do not immediately suggest a metabolic problem.
A team of researchers at Salford Royal Hospital in the United Kingdom set out to explore this hidden diversity by studying a group of thirty-one adults who had been diagnosed with this condition. While the syndrome is often thought of as a childhood illness, these patients had reached adulthood, some only receiving their diagnosis after decades of unexplained symptoms. The researchers reviewed the medical records of this group to understand the full range of how the disease manifests in grown-ups, how long it took to find the answer, and whether the specific genetic error a person carried could predict their symptoms. They found that the path to a diagnosis was often long and winding, with a median delay of six and a half years between the first sign of trouble and the final confirmation. For some individuals, this wait stretched to nearly fifty years, a testament to how easily the subtler signs of the disease can be missed by clinicians who are trained to look for the classic, severe presentation seen in babies.
The study revealed that the adult patients fell into three main groups based on their primary symptoms. Some suffered mainly from seizures, others from movement disorders such as tremors, unsteadiness, or involuntary muscle contractions, and a third group experienced a mix of both. Interestingly, the group with mixed symptoms of seizures and movement issues tended to get a diagnosis the fastest, in about three and a half years on average. Those with movement problems alone faced the longest wait, often a decade or more, because their symptoms were frequently mistaken for other neurological conditions. The researchers also discovered a clear link between the type of genetic error and the severity of the illness. Patients with genetic changes that completely stopped the production of the glucose transporter protein tended to have symptoms start very early in life, often before age four, and were more likely to have seizures and significant learning difficulties. In contrast, those with genetic errors that allowed some of the protein to still function, though imperfectly, often developed symptoms later and were more likely to struggle primarily with movement issues that worsened with exercise.
Treatment for this condition is unique because it does not rely on fixing the broken door, but rather on changing the fuel the brain uses. The standard therapy is a ketogenic diet, a strict eating plan high in fats and very low in carbohydrates. This forces the body to produce ketones, an alternative fuel source that the brain can use even when glucose cannot get in. The study showed that most patients who tried this diet saw improvements, with many experiencing fewer seizures, better movement control, and clearer thinking. However, sticking to such a restrictive diet is difficult, especially for adults managing their own lives. The researchers noted that many patients struggled with the lack of food variety, the burden of planning every meal, and the social isolation of eating differently from everyone else. Some had to stop the diet entirely, while others found a middle ground, using special supplements to get the benefits without the extreme restrictions. The study also highlighted that pregnancy in women with this condition requires careful management, as the increased energy demands of carrying a baby can trigger seizures if the diet is not carefully monitored.
Perhaps the most encouraging finding was that a diagnosis of this condition does not mean a life of severe disability. While many patients in the group had intellectual disabilities or developmental delays, the researchers found that several were attending college or university, and many lived independently or with minimal support. The ability to function varied widely, even among family members who shared the exact same genetic mutation, suggesting that other factors influence how the disease plays out. The researchers concluded that the key to helping more people lies in widening the net of what doctors look for. By recognizing that movement disorders and learning difficulties can be signs of a glucose transport problem, even in the absence of seizures, clinicians can identify patients much sooner. The study suggests that as genetic testing becomes more common and families are screened when one member is diagnosed, more adults with mild or atypical forms of the disease will be found, allowing them to access treatments that can significantly improve their quality of life.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.